The Inotrope Evaluation and Research Patient Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

129 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-25

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The INTERPRET Inotrope Evaluation and Research Patient Registry is a longitudinal, observational study designed to look at the demographics and outcomes of heart failure patients on inotropic therapy administered in the home or infusion suite setting. The data gathered in this registry will provide information on how a patient's quality of life and symptoms change over time while on inotrope therapy, and help healthcare providers to have a better understanding of the benefits and risks associated with bridge-to-treatment and palliative care.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure

NCT02767024

Acute Heart Failure

WITHDRAWN PHASE4

Hyperemic Efficacy of IV Adenosine in HFrEF

NCT03235700

Heart Failure With Reduced Ejection Fraction Coronary Artery Disease

UNKNOWN NA

A Study of CLR325 in Chronic Stable Heart Failure Patients.

NCT02696967

Chronic Stable Heart Failure

COMPLETED PHASE2

Chronotropic Incompetence in Patients With HFpEF

NCT02524145

Heart Failure

COMPLETED NA

Spironolactone Therapy in Chronic Stable Right HF Trial

NCT03344159

Chronic Right-Sided Heart Failure Pulmonary Arterial Hypertension Pulmonary Hypertension, Primary, 2 +3 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eligible patients will be consented by the site investigator or staff to participate in the Registry at the time of referral for home care. Clinical data, including dosing, symptom severity, lab values, and hospitalizations, along with data on quality-of-life and patient compliance with treatment, will be collected by the home care nurses and pharmacists. The Registry's goal is to significantly contribute to the medical understandings of heart failure treatment and to improve the quality of care for heart failure patients in the United States through active publication of registry findings and disease management approaches.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inotrope

Home intravenous infusion of Dobutamine, Dopamine, or Milrinone

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Primacor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient must be prescribed inotropic treatment (milrinone, dobutamine or dopamine)
* Patient must be referred to Coram for this treatment in an alternate site of care, either home or infusion suite
* Patient must be willing to receive care and comply with the teaching and training necessary to administer treatment
* Patient is age 18 or over

Exclusion Criteria

* Patient is unable to start, or stops taking, inotropic medication
* Patient and/or patient insurance will not cover cost of home inotropic treatment with Coram, or patient elects not to start treatment
* Patient is under the age of 18

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No